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Alternative pathway activation of complement by cultured human
proxhnal tubular epithelial cells. Human proximal tubular epithelial cells
(PTEC) incubated with normal human serum (NHS) were found to fix
on their surface C3, properdin, terminal complement components and
C5b-9 MAC neoantigen, but not Clq and C4, by immunofluorescence.
Complement fixation was abrogated if PTEC were incubated with
EDTA-treated NHS or C3-deflcient human serum, but not with Mg
EGTA-treated NHS or Clq-deficient human serum, showing the prev-
alent activation of the alternative pathway of complement. This event
was followed by marked cytoskeleton alterations with disruption of the
actin cortical network, redistribution of actin throughout the cytoplasm
and formation of blebs, and by cell cytolysis. In addition, superoxide
anion and hydrogen peroxide production and chemiluminescence re-
sponse were detected in consequence of MAC insertion on PTEC
plasma membrane. The dependency on MAC of the observed biological
effects of complement fixation on PTEC surface was shown by using
sera selectively deficient of terminal components of complement (C6 or
C8), and therefore unable to form the C5b-9 MAC, and by restoring the
ability to form MAC after addition of purified C6 or C8. The possible
pathogenetic relevance of these observations in tubulointerstitial injury
occurring in patients with complementuria due to non-selective protein-
uria, is discussed.
Tubular interstitial injury, rather than glomerular damage,
was shown to correlate with renal functional impairment and
progression of a variety of glomerulonephritis [reviewed in 1]. It
was suggested that alteration in glomerular functions and/or
extension of the immune injury to the interstitium may promote
tubulointerstitial damage [1].
One of such alterations is the loss of glomerular permeselec-
tivity leading to proteinuria [2—6]. In several experimental
models tubulointerstitial damage correlates with the severity of
proteinuria [4—61, suggesting that plasma proteins escaped into
urine, such as lipoproteins [7], transferrin [8] and complement
fractions [9, 10], and may account for the tubular injury.
Histological studies demonstrated that the alternative pathway
of complement can be directly activated by the brush border of
proximal tubules of normal rat [11] and human kidney [9]. The
occurrence of tubular deposits of complement in patients with
Received for publication June 7, 1993
and in revised form September 7, 1993
Accepted for publication September 9, 1993
© 1994 by the International Society of Nephrology
altered glomerular permeability was shown to correlate with
urinary excretion of native and breakdown products of comple-
ment [10]. Recently, the urinary excretion of C5b-9 membrane
attack complex (MAC) and its deposition in tubular epithelium
was detected in proteinuric nephropathies either in the presence
or in the absence of MAC glomerular deposition [12, 13]. Thus,
the increased urinary excretion of MAC may reflect an immune
glomerular activation and/or an activation of complement by
the tubular brush border. However, the pathogenetic implica-
tions of complement activation by proximal tubules are at
present unknown.
The aim of the present study was to investigate whether
cultured human proximal tubular cells (PTEC) could activate
complement with fixation of MAC on their surface and whether
these events may lead to cell stimulation with generation of
reactive oxygen species (ROS) and/or to cell injury.
Methods
Materials
Ferricytochrome c (Type IV), superoxide dismutase, phenol
red, 5,5-dimethylpyrroline N-oxide (DMPO), horseradish per-
oxidase, catalase, luminol, human anti-myosin antibodies,
FITC-conjugated anti-mouse and anti-goat antibodies were
purchased from Sigma Chemical Co. (St. Louis, Missouri,
USA). Anti-human Clq, C4, C3, IgG, IgA and 1gM antibody
were from Behnngwerke AG (Marburg, Germany); anti-human
properdin, C3, CS, C7, C8 antibodies were from Miles-Yeda
(Kickatweizman, Rehovot, Israel). Anti-human C9 monoclonal
antibody was from ICN Flow (Milano, Italy). Monoclonal
mouse anti-human C5b-9 reacting with a neoepitope in acti-
vated C9 complement exposed in the solid phase and membrane
form and in the fluid phase form of the terminal complement
complex but not in native C9 [14, 15], was from Dako s.p.a.
(Milano, Italy). Human factor VIII antiserum was from Nordic
Immunology (Tilburg, The Netherlands); mouse monoclonal
anticytokeratin antibody was from Labometrics (Milano, Italy).
The specificity of these reagents was established by immuno-
diffusion and by immunoelectrophoresis. Before use the re-
agents were appropriately adsorbed in order to avoid nonspe-
cific staining.
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Table 1. Human complement components on PTEC or HUVEC
C5b-9
MAC
C3 Properdin Clq C4 C5 C8 C9 neoantigen
Treatment of PTEC
NHS +++ +++ 0 0 ++ +++ +++ +++
HIHS 0 0 0 0 0 0 0 0
NHS + EDTA 0 0 0 0 0 0 0 0
NHS+MgEGTA +++ +++ 0 0 ++ +++ ++ +++
Clq-DEFHS ++ ++ 0 0 ++ +-I- ++ ++
C3-DEF HS 0 0 0 0 0 0 0 0
C6-DEF HS + + + + + 0 0 + + 0 0 0
C6-DEFHS+C6 +++ ++ 0 0 ++ ++ ++ ++
C8-DEFHS +++ +++ 0 0 ++ 0 0 0
C8-DEFHS+C8 +++ +++ 0 0 ++ ++ ++ +++
Treatment of HUVEC
with NHS +1— 0 0 0 0 0 0 0
In vitro fixation of various human complement components on the surface of VFEC or of HUVEC incubated at 37°C for one hour with 25% NHS,
HIHS, NHS with 10 m EDTA, NHS with 5 ms Mg-EGTA, Clq-def HS, C3-def HS, C6-def HS, C6-def HS with 50 pg/mI C6, C8-def HS, C8-def
HS with 70 pg/mI C8 was studied by immunofluorescence as described in the Methods.
Fig. 1. Micrographs illustrating the results of immunofluorescence tests performed on cultured PTEC. (A) C3 fixation on the surface of PTEC
incubated at 37°C for 1 hour with 25% NHS; (B) negative control for C3 fixation after PTEC incubation at 37°C for 1 hour with 25% HIHS (x 400).
PTEC preparation and characterization and forced through a graded series of meshes to remove
interstitial fragments and glomeruli [16]. PTEC were pelleted,
Surgical specimens of kidneys were used as source for resuspended and plated in RPM! 1640 supplemented with 17%
establishing cultures. The fibrous capsule was removed and fetal calf serum (Sigma), 50 U/mI penicillin, and 50 pg/ml
portions of tissue were dissected from the outer cortex, minced streptomycin; culture flasks were kept in a 95% air-5% CO2
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Fig. 2. The immunofluorescence micrograph shows fine granular deposits of CSb-9 MAC neoantigen on the plasma membrane of PTEC incubated
at 37"C for 1 hour with 25% NHS (x 400).
environment at 37°C. Confluent monolayers were passaged
after treatment with 0.05% trypsin-0.02% EDTA (ICN Flow).
Endotoxin was not detectable in either preparation when tested
by the limulus assay. PTEC were characterized on the basis of:
(a) minimal staining for desmin and negative staining for factor
VIII-vWF [16]; (b) strong staining for cytokeratin and actin
[16]; (c) staining of 90 to 96% of cells for alkaline phosphatase
as determined by the naphtal AS-MX method [17]; (d) increased
cAMP production after stimulation with 100 nM PTH but not 1
/SM ADH [17].
Sources of complement
For in vitro experiments the following sera were used as a
source of complement: (1) normal human sera pooled from 10
healthy donors; in some experiments sera were complement-
inactivated by heating at 56°C for 1 hour (HIHS); (2) Clq-
deficient human serum (Clq-def HS), C3-deficient human se-
rum (C3-def HS), C6-deficient human serum (C6-def HS),
C8-deficient human serum (C8-def HS) were purchased by
Sigma Chemical Co. The CH50 levels in sera were determined
by hemolytic assay, as previously described [18]. CH50 level of
NHS was 45 4.8 U/mi. C6-def HS and C8-def HS had no
detectable hemolytic activity. Restoration of the normal hemo-
lytic activity was obtained after addition of 50 pgIml human
purified C6 (Sigma) to C6-def HS or 70 jsg/ml human purified C8
(Sigma) to C8-def HS.
Experimental protocol
106 confluent PTEC, plated on 35 mm plastic dishes, were
incubated for the indicated periods of time at 37°C with 25%
NHS, HIHS, Clq-defHS, C3-defHS, C6-defHS, C8-defHS or
with C6- or C8-def HS reconstituted with purified C6 or C8,
respectively. Human endothelial cells from umbilical cord vein
(HVEC) were used as control.
Immunofluorescence studies
After stimulation, cells were fixed in 3% paraformaldehyde in
PBS (pH 7.6) containing 2% sucrose for five minutes at 4°C and
then stained for Clq, C4, C3, IgG, IgA, 1gM, properdin, C5, C7,
C8, C9 or C5b-9 neoantigen. Immunofluorescence tests on
PTEC in culture and the relevant control experiments were
performed as previously described [19].
Cytoskeleton alterations were studied on fixed PTEC after
permeabilization with 0.1% triton X-100 in PBS and stained for
F-actin with 2 pg/ml FITC-conjugated phalloidin (F-PHD) [20].
Assay for cytotoxicity
The cytotoxic effect of complement on PTEC in culture was
measured as percentage of 5tCr release in the supernatant, as
previously described [21]. Confluent cultures of PTEC in
35-mm culture dishes were incubated for two hours at 37°C with
250 Ci of Na5 CrO4. The cells were washed five times with
a 4tr -
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Fig. 3. The immunofluorescence micrograph demonstrates absence of C5b-9 MAC neoantigen deposition on the surface of PTEC incubated at
37°C for 1 ourwith 25% C6-defHS (X 400).
Fig. 4. The immunofluorescence micrograph
shows the formation of C5b-9 MAC
neoantigen-containing blebs on the surface of
PTEC incubated at 37°C for 1 hour with 25%
C6-defHS after reconstitution with 50 rsg
purffied human C6 (x 400).
Eagle's modified Dulbecco medium (GIBCO, Grand Island,
New York, USA) supplemented with 10% complement-inacti-
vated fetal calf serum and covered with 1 ml of the same
medium. After appropriate treatment, the cell-free supernatant
was collected and the radioactivity was counted in a gamma
counter (Packard autogamma scintillation spectrometer, Pack-
ard Instrument Co., Clarence, New York, USA). After treat-
ment with 5% Triton X-l0O, the radioactivity that remained
associated with the cells was also measured. The spontaneous
release of 51Cr into the supernatant and the amount of radioac-
tivity associated with untreated cells were evaluated in separate
wells. The percentage of 51Cr release in each individual well
was calculated, assuming as 100% the radioactivity in the
supernatant plus the value extract from the cells.
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Fig. S. The immunofluorescence micrograph demonstrates the absence of IgG deposition on the surface of PTEC incubated at 37°C for 1 hour
with 25% NHS; similar results were obtained for IgA and 1gM (x 400).
Fig. 6. F-actin distribution in fixed and permeabilized PTEC showing the normal distribution of actin-containing stress fibers at the periphery of
the cells in a ring-like pattern. The same pattern was observed after PTEC incubation at 37°C for 1 hour with 25% HIHS or C6-def HS (X 400).
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Fig. 7. Altereddistribution of F-actin after exposure of PTEC to 5% NHS for 1 hour at 37°C. The cortical network of actin-containing stress fibers
tends to disappear, cells separate from each other, become round and develop blebs (x 400).
Reactive oxygen species assays
Superoxide anion (02) assay. Production of 02 was mea-
sured as the superoxide dismutase inhibitable reduction of
ferricytochrome C [221. Cell monolayers were incubated at 37°C
with Tyrode's buffer containing 80 j.M cytochrome C and
appropriately stimulated. Basal O, production was assessed in
the absence of any of the stimulating factors. Supernatants were
removed and centrifuged and the absorbance was measured in
a spectrophotometer at 550 nm. The extinction coefficient of
ferricytochrome C at 550 nm was taken as 2.1 x i0 M1 cm.
Protein content of the monolayer was measured by the Lowry
technique. 02 production was expressed as n of cytochrome
C reduced/mg protein/time [22].
Hydrogen peroxide (11202) assay. Production of H202 was
measured by the method of Pick and Keisari [23]. The assay is
based on HRPO-mediated oxidation of phenol red by H20,
resulting in a production with maximal adsorbance at 610 nm.
Adsorbance is compared to that of a standard curve of hydro-
gen peroxide. PTEC were incubated with 0.28 m phenol red in
PBS, containing 50 g/ml of HRPO. At the specified time,
supernatants were removed from the cell monolayers, centri-
fuged, alkalinized with 10 4u of 1 N NaOH and adsorbance
determined at 610 nm. Results were expressed as flM H202
produced/mg protein/time [22].
Cheiniluminescence
Luminol (50 xM) enhanced chemiluminescence was mea-
sured on 5 x l0 EDTA-detached and suspended PTEC incu-
bated as described in the experimental protocol in Hepes-
buffered Krebs medium containing 0.05% BSA in a LKB 1250
luminometer. Data are expressed in mVolt [24].
Statistical analysis
All data within groups were analyzed by one-way analysis of
variance (ANOVA) with Dunnett's or Newman-KeuI's multi-
ple-comparison tests where appropriate. Values are given as
mean SD. Values of P <0.05 were considered statistically
significant.
Results
The results of immunofluorescence studies are summarized in
Table 1. PTEC incubated with NHS but not with HIHS fixed C3
(Fig. 1) and properdin, but not Clq and C4, on their surface.
The complement activation occurred via the alternative path-
way since it was not prevented by 5 m Mg-EGTA or by
incubation with Clq-def HS (Table 1). In contrast, 10 mi
EDTA and C3-def HS completely prevented complement fixa-
tion. As shown by the staining for CS, C8, C9 (Table 1) and
C5b-9 MAC neoantigen (Fig. 2), the terminal components of
complement inserted in PTEC plasmamembrane. As shown in
Figure 2, numerous plasma membrane blebs containing C9
neoantigen were observed. C5b-9 MAC neoantigen was not
detectable when PTEC were incubated with C6- or C8-def HS
(Fig. 3, Table 1). The immunofluorescence staining for CSb-9
MAC neoantigen was restored after addition of purified human
C6 (Fig. 4) or C8 (Table 1), respectively, to C6- or C8-def HS.
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Fig. 8. (A) Percentage of51Cr release from PTEC after incubation for
1 hour at 37°C without any addition (A) or with addition of 25% NHS
(B), HJHS (C), C6-defHS (D), C6-defHS plus 50 jig/mi C6 (E), NHS
plus 100 jig/miSOD (F), NHS plus 100 isg/ml catalase (G), NHS plus
10mM DMPO (H). ANOVA with Newman-Keul's multiple-comparison
test was performed within groups: A versus B, C, D, E, F, G or H (*P
<0.05); B versus C, D, E, F, 0 or H (+P <0.05) D versus E (@P <
0.05). Panel (B) Percentage of 51Cr release from PTEC after incubation
for 1 hour at 37°C with various dilutions of NHS (hatched bars) or
Clq-def HS (open bars), and from HUVEC (solid bars) after incubation
for 1 hour at 37°C with various dilutions of NHS. ANOVA was
performed between PTEC incubated with NHS and PTEC incubated
with Clq-def HS (not significant), and between PTEC and HUVEC (*P
<0.05).
In all the experimental conditions, the staining of P'FEC for
IgG, IgA or 1gM was consistently negative (Fig. 5). Moreover,
control immunofluorescence stainings performed with irrele-
vant monoclonal mouse IgG were negative. Complement fixa-
tion was not observed after incubation of HUVEC with a
source of complement following the same protocol used for
PTEC (Table 1).
The incubation of PTEC with NHS induced changes in the
a)
C,)
Cu
a)
a)
0
cell cytoskeleton. Actin-containing stress fibers which in tIn-
stimulated PTEC were concentrated at the periphery of the
cells in a ring-like pattern (Fig. 6), were disrupted in 60 11%
of the cells after incubation for one hour with 5% NHS (Fig. 7),
a concentration that was found to induce only minimal cyto-
toxic effects, as detected by Trypan blue staining (10 3% of
the cells) and 51Cr release (Fig. 8B). Stress fibers were de-
creased and randomly distributed in the cytoplasm with disap-
pearance of the cortical network. Cells tended to lose the
reciprocal contact, reducing their surface to became round and
developed blebs (Fig. 7). These alterations were absent when
cells were incubated with HIHS or with C6-def HS and were
restored by addition of purified C6 to the C6-def HS. For
concentration of 25% NHS the deposition of MAC on the
plasma membrane of PTEC as well as changes in the cytoskel-
eton distribution were associated with cytotoxic effects, as
detected by Trypan blue staining of lethally injured cells (49
6%). Cell cytotoxicity was quantitated measuring the release of
51Cr. As shown in Figure 8A, incubation of PTEC with NHS,
but not with HIHS, induces release of 51Cr. The release of 51Cr
became significant after 20 minutes incubation and reached the
plateau after 60 minutes (Fig. 9). That cytolysis is mediated by
the MAC was shown by the absence of cell lysis when C6-def
HS was used and by restoration of cytolytic activity with
human purified C6 (Fig. 8A). Similar results were obtained with
C8-def HS and with C8-def HS reconstituted with human
purified C8 (data not shown). Cytotoxicity studies performed in
parallel with Clq-def HS and NHS at various dilutions con-
firmed that the complement activation was independent from
the classical pathway activation (Fig. 8B). Figure 8B also shows
the absence of cell lysis when the HUVEC were incubated with
various dilutions of NHS, suggesting that the alternative path-
way activation and the consequent MAC-dependent cytolysis
was unique to the PTEC.
Experiments performed in the presence of superoxide dismu-
tase, catalase or DMPO suggested that complement induced
cytolysis may at least in part depend on ROS generation (Fig.
8A). Production of 02 and H202 from PTEC was detectable 10
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Fig. 9. Percentage of 51Cr release from PTEC incubated at 37°C for
various periods of time without any addition (A) or with addition of 25%
NHS () or HIHS (0).
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Fig. 11. Chemiluminescence of PTEC incubated at 37°C for various
periods of time with 25% NHS (0), HIHS (0), C6-defHS (N), C6-def
HS reconstituted with 50 pg/mI C6 (A) or without any addition (L).
minutes after incubation with NHS (data not shown) and
reached a plateau after one hour. Figure 10 shows the produc-
tion of significant amounts of 02 and H202 from PTEC after
one hour incubation whit NHS. In contrast, incubation with
HIHS did not stimulate significant ROS generation. The amount
of 02 (Fig. 1OA) and H202 (Fig. lOB) produced by PTEC was
significantly reduced using C6-def HS. The addition of purified
C6 completely restored the generation of ROS. HUVEC after
incubation with NHS did not produce significant amounts of
02 and H202. NHS, but not HIHS or C6-def HS, stimulated
chemiluminescence of PTEC in the presence of luminol. Re-
constitution of C6-def HS with human purified C6 restored
generation of chemiluminescence by PTEC (Fig. 11).
Discussion
Incubation of sections of frozen normal rat [11] and human
kidney tissue [9] with fresh serum is associated with the
activation of the alternative pathway of complement by the
brush border of proximal tubular cells. Studies on patients with
nonselective proteinuna demonstrated a positive correlation
between the occurrence of tubular C3 deposits and the urinary
complement excretion, as well as with the presence of C3
breakdown products in urine, suggesting that complement
components once filtered through the glomerular barrier might
be activated by the brush border of the proximal tubules [10].
Baker et al demonstrated the formation and stabilization of
cell-bound C3 convertase activity on heat-killed human kidney
cells, suggesting that cell injury may locally intensify C3-
activation [25—27]. The results of the present study extend these
observations by showing that cultured human proximal tubular
epithelial cells activate complement via the alternative pathway
leading to binding of the CSb-9 MAC to the cell surface. These
events are followed by marked cytoskeleton alterations with
disruption of the cortical network of actin-containing stress
fibers, redistribution of actin within the cytoplasm, formation of
blebs and cytolysis. That these alterations are produced by
MAC is shown by the absence of cytolysis after cell incubation
with sera deficient of the C6 or C8 components of complement,
and thus they are incapable of forming the C5b-9 MAC.
Furthermore, the present study demonstrates that the suscep-
tibility to cell injury is restored when sera were reconstituted
with the purified C6 or C8 complement fractions. MAC could
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Fig. 10. Production of °2 (A) and 11202 (B)
from PTEC after incubation for 1 hour at
37°C without any addition (None) or with
addition of 25% NHS, HIHS, C6-def HS or
C6-defHS plus 50 pg/mI C6 and from
HUVEC after incubation for 1 hour at 37°C
without any addition (None) or with addition
of 25% NHS. ANOVA with Newman-Keul's
multiple-comparison test was performed
within treated groups versus None (*P <
0.05); NHS versus HIHS, C6-def HS or C6-
def HS plus C6 (+P < 0.05); C6-def HS
versus C6-def HS plus C6 (@P < 0.05).
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produce injury either by stimulating the release of other medi-
ators or by producing direct plasma membrane damage.
Insertion of C5b-9 MAC into the lipid bilayer of glomerular
epithelial cells was shown to induce structural changes compa-
rable to membrane defects produced in erythrocytes incubated
with specific antibodies and complement [211. Alternatively,
MAC may produce cell injury by stimulating the release of
cytokines or by generation of autacoids and reactive oxygen
radicals [28—32]. The present experiments, performed with C6
deficient and C6 reconstituted sera, indicated that MAC inser-
tion in the plasma membrane of PTEC stimulates synthesis of
reactive oxygen radicals. However, experiments performed
with superoxide dismutase and catalase [33] suggest that the
cytolytic effect of MAC is only partially dependent on reactive
oxygen radical generation and that the direct mechanism of cell
injury [34] is prevalent. Nevertheless, if oxygen radical gener-
ation would occur in vivo after complement fixation by proximal
tubular cells in patients with nonselective proteinuria, it may
favor development of inflammatory lesions in the interstitium.
Indeed, it was proposed that hydroxyl ions and other oxidants
may cause tubulointerstitial injury in proteinuric states [re-
viewed in 35]. This may be catalyzed by iron released from
transferrin reabsorbed by PTEC [8, 36] or as proposed herein
by MAC insertion in the PTEC plasma membrane. Evidence
obtained in vivo supports the contention that MAC is activated
in membranous glomerulonephritis and other proteinuric glom-
erulopathies [12, 13]. In patients with membranous nephropa-
thy, increased urinary excretion of C5b-9 is associated with an
increased deposition of MAC in glomerular and tubular epithe-
hum and correlates with the severity of the disease [13]. In this
disease C5b-9 urinary excretion may reflect the immune com-
plex-mediated intraglomerular activation of terminal compo-
nents of complement, similar to that observed in Heymann
nephritis [37—39]. However, in other proteinuric states, such as
diabetic and focal glomerulosclerosis, an increased urinary
excretion of C5b-9 occurs in the absence of glomerular deposi-
tion of MAC [13], suggesting that it may result from the
activation of complement by tubular brush border. By either
mechanism, terminal complement activation may contribute to
tubular interstitial injury, In the present study we have not
explored the production of cytokines or autacoids by tubular
epithelial cells. However, it is well-established on other cell
types that MAC may stimulate production of cytokines and
autacoids that can act as chemoattractants for leukocytes and
monocytes [28—32]. Furthermore, by inducing alterations in the
cytoskeleton of epithelial cells, MAC plays a critical role in
maintaining cell polarity [40] and may affect tubular cell func-
tions. This possibility is supported by results of micropuncture
studies demonstrating functional as well as morphological le-
sions induced by intraluminal perfusion of proximal tubules
with fresh serum [41].
In conclusion, the results of the present study provide an
experimental support for the hypothesis that in patients with
urinary excretion of complement components because of a
nonselective proteinuria, tubulointerstitial injury may be, at
least in part, sustained from direct activation of the complement
system by the plasma membrane of proximal tubular cells. The
biological effects of such complement activation are related to
insertion of MAC in the cell plasma membrane as shown by
dependency of redistribution of cell cytoskeleton, cytolysis and
generation of ROS on the activation of MAC.
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